415 related articles for article (PubMed ID: 22715097)
1. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
2. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
3. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
4. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
6. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
7. Fibrillar aggregates of the tumor suppressor p53 core domain.
Ishimaru D; Andrade LR; Teixeira LS; Quesado PA; Maiolino LM; Lopez PM; Cordeiro Y; Costa LT; Heckl WM; Weissmüller G; Foguel D; Silva JL
Biochemistry; 2003 Aug; 42(30):9022-7. PubMed ID: 12885235
[TBL] [Abstract][Full Text] [Related]
8. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.
Kovachev PS; Banerjee D; Rangel LP; Eriksson J; Pedrote MM; Martins-Dinis MMDC; Edwards K; Cordeiro Y; Silva JL; Sanyal S
J Biol Chem; 2017 Jun; 292(22):9345-9357. PubMed ID: 28420731
[TBL] [Abstract][Full Text] [Related]
9. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
10. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
Lee AS; Galea C; DiGiammarino EL; Jun B; Murti G; Ribeiro RC; Zambetti G; Schultz CP; Kriwacki RW
J Mol Biol; 2003 Mar; 327(3):699-709. PubMed ID: 12634062
[TBL] [Abstract][Full Text] [Related]
11. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
12. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
13. Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils.
Yang DS; Saeedi A; Davtyan A; Fathi M; Sherman MB; Safari MS; Klindziuk A; Barton MC; Varadarajan N; Kolomeisky AB; Vekilov PG
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33653952
[TBL] [Abstract][Full Text] [Related]
14. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
15. The Japanese mutant Aβ (ΔE22-Aβ(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Aβ(1-40) into atypical fibrils by ΔE22-Aβ(1-39).
Cloe AL; Orgel JP; Sachleben JR; Tycko R; Meredith SC
Biochemistry; 2011 Mar; 50(12):2026-39. PubMed ID: 21291268
[TBL] [Abstract][Full Text] [Related]
16. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 5 phosphorylation of familial prion protein mutants exacerbates conversion into amyloid structure.
Rouget R; Sharma G; LeBlanc AC
J Biol Chem; 2015 Feb; 290(9):5759-71. PubMed ID: 25572400
[TBL] [Abstract][Full Text] [Related]
18. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC; de Oliveira GA; Cino EA; Soares IN; Rangel LP; Silva JL
Cold Spring Harb Perspect Biol; 2016 Oct; 8(10):. PubMed ID: 27549118
[TBL] [Abstract][Full Text] [Related]
19. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53.
Forget KJ; Tremblay G; Roucou X
PLoS One; 2013; 8(7):e69242. PubMed ID: 23844254
[TBL] [Abstract][Full Text] [Related]
20. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
